Destiny Pharma is a clinical phase biotechnology company dedicated to the development of novel anti-infectives.

Our lead asset, XF-73, is currently recruiting patients into a Phase 2b clinical trial for the prevention of post-surgical infection.

We are looking to build a portfolio of novel antimicrobial drug products from our XF drug platform that can access markets closed to traditional antibiotics due to the threat of antimicrobial resistance (AMR), generic competition and pricing challenges.

Our XF drug platform acts via an ultra-rapid action that kills targeted bacteria (including antibiotic resistant strains) leaving the bacteria unable to mount a resistance.

Destiny is also collaborating with SporeGen on a novel treatment for the prevention of COVID-19 and similar respiratory viral infections using a Bacillus based approach. This project is at the preclinical development stage.